Financial Review: RTI Surgical (RTIX) versus NanoVibronix (NAOV)
RTI Surgical (NASDAQ:RTIX) and NanoVibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
Institutional and Insider Ownership
68.5% of RTI Surgical shares are held by institutional investors. Comparatively, 14.2% of NanoVibronix shares are held by institutional investors. 4.4% of RTI Surgical shares are held by company insiders. Comparatively, 18.7% of NanoVibronix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares RTI Surgical and NanoVibronix’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|RTI Surgical||$279.56 million||1.06||$6.27 million||$0.05||93.00|
RTI Surgical has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than RTI Surgical, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
RTI Surgical has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500.
This table compares RTI Surgical and NanoVibronix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for RTI Surgical and NanoVibronix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RTI Surgical beats NanoVibronix on 9 of the 11 factors compared between the two stocks.
About RTI Surgical
RTI Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company's implants are used in the fields of sports medicine, general surgery, spine, orthopedic, trauma, and cardiothoracic procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force, as well as through a network of independent distributors. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.